Comparison of the frequency of therapeutic target blood pressure between three studies and its association with the variables analyzed

Authors

  • Solange Houssay José Ramos Mejía Hospital, City of Buenos Aires, Argentina
  • Silvana Milrad M. Rocca Hospital, City of Buenos Aires, Argentina
  • Ángela Luongo Pueyrredón Medical Offices, Banfield, Province of Buenos Aires, Argentina
  • Sandra Maserati Santa María de la Salud Space, San Isidro, Province of Buenos Aires, Argentina
  • Julieta Méndez University of Buenos Aires (UBA), City of Buenos Aires, Argentina
  • Marina Margossian Ceiba, City of Buenos Aires, Argentina
  • Carolina Gómez Martin CENDIA, Concordia, Entre Ríos, Argentina
  • Julio Bragagnolo José Ramos Mejía Hospital (HRM), City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v58i3.1140

Keywords:

type 2 diabetes, blood pressure goals, associated factors, treatment, adherence

Abstract

Introduction: blood pressure (BP) control prevents the onset and progression of chronic complications of type 2 diabetes mellitus (DM2).

Objectives: to compare the frequency of BP in therapeutic target between three studies conducted in adults with DM2 in Argentina, and its association with the variables analyzed.

Materials and methods: cross-sectional, comparative design of three multicenter studies, which included adults with DM2 assisted by specialists in 2006-2011 and 2018. Target: BP <140-90 mmHg. The frequency of BP in target was compared in relation to the differences between the study populations, duration of DM2, chronic complications, treatment strategies, adherence and quality of life. Adherence and quality of life questionnaires were applied. History, clinical examination and laboratory tests were analyzed.

Results: of 4709 patients, 83% had arterial hypertension (HTN). The BP goal was achieved by 64.7%, 67.6% and 52.4% in 2006, 2011 and 2018 respectively (p<0.0001). Regarding the pharmacological treatment of HTN, without treatment: 3%, 2% and 6.5% (2006, 2011 and 2018; p=0.0001). The most commonly used antihypertensives in 2006, 2011 and 2018 were: ACEI decreasing (p=0.0001), followed by ARBs increasing (p=0.0001); Thiazides (p=0.0001) and atenolol (p=0.001) decreased, and carvedilol (p=0.0001) and amlodipine (p=0.013) increased. BP achievement was associated with lower body mass index (BMI) and waist circumference (p=0.0001), greater physical activity (p=0.0001), use of antihypertensives (p=0.0001), quarterly check-ups (p=0.0001), HbA1c <7% (p=0.0001), coronary heart disease (p=0.001) and having health insurance (p=0.001).

Conclusions: lower achievement of the therapeutic BP goal was associated with central obesity and nephropathy; the variables associated with greater achievement were: physical activity, taking antihypertensives, periodic check-ups and private health insurance.

Author Biographies

Solange Houssay, José Ramos Mejía Hospital, City of Buenos Aires, Argentina

Medical specialist in Nutrition and Internal Medicine, University of Buenos Aires (UBA), deputy director of the Nutrition Program (UBA), Medical Staff, Nutrition and Diabetes Unit

Silvana Milrad, M. Rocca Hospital, City of Buenos Aires, Argentina

Medical specialist in Nutrition and Internal Medicine, University of Buenos Aires (UBA), Head of the Emergency Service

Ángela Luongo, Pueyrredón Medical Offices, Banfield, Province of Buenos Aires, Argentina

Specialist in Nutrition, University of Buenos Aires (UBA), Doctor

Sandra Maserati, Santa María de la Salud Space, San Isidro, Province of Buenos Aires, Argentina

Master in Diabetes, Favaloro University, Director of the Multimodal Center for Overweight, Obesity and Diabetes

Julieta Méndez, University of Buenos Aires (UBA), City of Buenos Aires, Argentina

Medical specialist in Internal Medicine and Nutrition, Associate Professor (Faculty of Medicine, UBA)

Marina Margossian, Ceiba, City of Buenos Aires, Argentina

Specialist in Nutrition, Master in Diabetes, University of El Salvador, Authorized teacher (University of Buenos Aires), Doctor of the Diabetes Service, Medicus, Diabetologist

Carolina Gómez Martin, CENDIA, Concordia, Entre Ríos, Argentina

Medical specialist in Internal Medicine, University of Buenos Aires (UBA), specialized in Diabetes (Argentine Diabetes Society), co-director of CENDIA

Julio Bragagnolo, José Ramos Mejía Hospital (HRM), City of Buenos Aires, Argentina

Specialist in Internal Medicine and Nutrition, Head of the Nutrition and Diabetes Unit, Adjunct Professor of Nutrition (University of Buenos Aires, UBA), Director of the Nutrition Program at HRM (UBA), Professor of the Master's Degree in Diabetes (University of Salvador)

References

I. Tercera Encuesta Nacional de Factores de Riesgo. Ministerio de Salud de la Nación. Disponible en: https://bancos.salud.gob.ar/recurso/3ra-encuesta-nacional-de-factores-de-riesgo-2013-presentacion (consultado mayo de 2024).

II. Cuarta Encuesta Nacional de Factores de Riesgo. Ministerio de Salud de la Nación. Disponible en: https://www.indec.gob.ar/ftp/cuadros/publicaciones/enfr_2018_resultados_definitivos.pdf (consultado mayo de 2024).

III. Ebstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403- 418.

IV. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994 Nov;17 Suppl 11:1247-5.

V. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 Aug 12;321(Suppl) 7258:412-9.

VI. Fang M, Wang D, Coresh J, et al. Trends in diabetes treatment and control in US adults, 1999-2018. N Engl J Med 2021 June 10;384(23):2219-2228. doi:10.1056/NEJMsa2032271.

VII. American Diabetes Association. 9. Cardiovascular disease and risk management. Standards of Medical Care in Diabetes 2018. Diabetes Care 2018;41(Sup1):S86-S104. doi: 10.2337/dc18-S009

VIII. Marín M, Bendersky M, Paez O, et al. Consenso Argentino de Hipertensión Arterial. Sociedad Argentina de Cardiología, Federación Argentina de Cardiología y Sociedad Argentina de Hipertensión Arterial. Rev Arg Cardiol 2018;86(Sup2). Acceso: mayo de 2024.

IX. Guía de Práctica Clínica Nacional sobre Prevención, Diagnóstico y Tratamiento de la Hipertensión Arterial, 2019. Buenos Aires, Argentina. Dirección Nacional de Promoción de la Salud y Control de Enfermedades Crónicas No Transmisibles. Ministerio de Salud y Desarrollo Social de la Nación. Disponible en: http://www.msal.gob.ar/ent/index. php/informacion-equipos-de-salud/guias-de-practica-clinica. Consultado: mayo de 2024.

X. Delucchi A, Marín M, Páez O, Bendersky M, Rodríguez P, et al. Principales conclusiones del Consenso Argentino de Hipertensión Arterial. Sociedad Argentina de Cardiología, Federación Argentina de Cardiología y Sociedad Argentina de Hipertensión Arterial. Hipertens Riesgo Vasc 2019;36(2):96‐109.

XI. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32(1):3‐15.

XII. Sabate E. Adherence to long-term therapies. Evidence for action. Geneve, World Health Organization. 2003. Disponible en: http://whqlibdoc.who.int/publications/2003/9241545992. Consultado marzo de 2024.

XIII. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74.

XIV. OMS-5. Índice de bienestar (versión 1998). Disponible en: https://www.psykiatri-regionh.dk/who-5/Documents/WHO5_ Spanish.pdf. Consultado marzo de 2024.

XV. Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. JAMA 2020;324:1190-200.

XVI. Cushman WC, Evans GW, Byington RP. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 April 29; 362(17):1575-1585. doi:10.1056/NEJMoa1001286.

XVII. Williams B, Mancia G, Spiering W, et al. Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial. Rev Esp Cardiol 2019;72(2):160.e1-e78.

XVIII. ElSayed NA, Aleppo G, et al. Cardiovascular disease and risk management: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl1):S158-S190

XIX. López González E, Ruiz ML, Luongo AM, et al; en nombre del Grupo FRADYC. Estudio multicéntrico de hipertensión arterial en pacientes con diabetes mellitus tipo 2 realizado por especialistas en Argentina. Revista ALAD 2011;1(1):29-35.

XX. Marin MJ, Fábregues G, Rodríguez PD, et al. Registro Nacional de Hipertensión Arterial. Conocimiento, tratamiento y control de la hipertensión arterial. Estudio RENATA. Rev Arg Cardiol 2012;80(2):121-129.

XXI. Visseren FLJ, Mach FO, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology (EAPC) and 12 medical societies. European Heart Journal 2021;00:1-111 doi: 101093/eurheartj/ehab484.

XXII. Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related complications. JAMA 2019;321(19):1867-1868. doi: 101001/jama.2019.3471.

XXIII. Delucchi AM, Majul CR, Vicario A. Registro Nacional de Hipertensión Arterial. Características epidemiológicas de la hipertensión arterial en la Argentina. Estudio RENATA-2. Rev Argent Cardiol 2017; 85:340-346. doi:107775/rac.v85.i4.11061.

XXIV. Houssay S, López González E, Luongo A, Milrad S y Linari MA. Diabetes tipo 2. ¿En la vida real es posible lograr la meta glucémica? Medicina (Buenos Aires) 2022;82:714-721.

XXV. Marx N, Federici M, Schütt K. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Societay of Cardiology (ESC). European Heart Journal 2023;00:1-98 doi: 101093/eurheartj/ehad192.

XXVI. OPS-OMS (oficina regional para las Américas). HEARTS Mejorar el control de la hipertensión en 3 millones de personas. Experiencias de los países sobre la elaboración e implementación de programas. Organización Panamericana de la Salud 2020.

XXVII. Giménez S, Piskorz D, Arrupe A, et al. Posición de la Federación Argentina de Cardiología acerca del Documento intersocietario que alerta sobre la alta prevalencia de complicaciones cardiovasculares y renales en personas con diabetes tipo 2 en Argentina. Rev Fed Arg Cardiol 2023;52(1).

XXVIII. Cosentino F, Verma S, Ambery Ph et al. Cardiometabolic risk management: insight from a European Society of Cardiology Cardiovascular Round Table. European Heart Journal 2023;00:1-16. doi: 10.1093/eurheartj/ehad445

XXIX. Mosenzon O, Alguwaihes A, Leon JLA, et al. CAPTURE Study Investigators. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol 2021 Jul 27;20(1):154. doi: 10.1186/s12933-021-01344-0.

XXX. Houssay S, Milrad S, Luongo A, et al; en nombre del Comité de Hipertensión Arterial y Factores de Riesgo Cardiovascular de la SAD. ¿Como individualizar el tratamiento de la hipertensión arterial en las personas con diabetes mellitus tipo 2? Rev Soc Arg 2022;56 (2):48-52.

XXXI. Yusuf S, Joseph Ph, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020;395(10226):795-808. doi: 10.1016/S014-6736(19)32008-2.

XXXII. Cardiovascular disease and risk management: Standards of Care in Diabetes 2023. Diabetes Care 2023;46(Suppl.1):S158-S190.

Downloads

Published

2024-09-17

How to Cite

Houssay, S., Milrad, S., Luongo, Ángela, Maserati, S., Méndez, J., Margossian, M., Gómez Martin, C., & Bragagnolo, J. (2024). Comparison of the frequency of therapeutic target blood pressure between three studies and its association with the variables analyzed. Journal of the Argentine Society of Diabetes, 58(3), 113–124. https://doi.org/10.47196/diab.v58i3.1140

Issue

Vol. 58 No. 3 (2024): September-December 2024

Section

Original article

License

Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Society of Diabetes

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Most read articles by the same author(s)

1 2 3 4 5 > >>